| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 03/24/2004 | EP1399167A1 Arylazo-substituted imidazole for the treatment of stress urinary incontinence |
| 03/24/2004 | EP1399165A2 Stabilized dispersion of phytosterol in oil |
| 03/24/2004 | EP1399155A2 Small molecules useful in the treatment of inflammatory disease |
| 03/24/2004 | EP1399151A2 A method for treating inflammatory diseases by administering a ppar-delta agonist |
| 03/24/2004 | EP1399149A2 Taxane prodrugs |
| 03/24/2004 | EP1399146A1 Novel compounds and compositions as cathepsin inhibitors |
| 03/24/2004 | EP1399137A1 Sulfonamides |
| 03/24/2004 | EP1349558A4 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 03/24/2004 | EP1303517B1 Indoloquinazolinones |
| 03/24/2004 | EP1200399B1 Vitamin d3 analogs |
| 03/24/2004 | EP1161232B1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists |
| 03/24/2004 | EP1097150B1 Imidazolyl derivatives |
| 03/24/2004 | EP1003505B1 Heterocyclic vinylethers against neurological disorders |
| 03/24/2004 | EP0850319B1 Method for modulating cell apoptosis |
| 03/24/2004 | CN1484652A Antibodies to human IL-1 beta |
| 03/24/2004 | CN1484646A Mikanolide derivatives their preparation and therapeutic uses |
| 03/24/2004 | CN1484644A Novel 7-azaindoles use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 03/24/2004 | CN1484640A Quinzolone derivatives as alpha IA/B adrenergic receptor antagonists |
| 03/24/2004 | CN1483466A Polygonum capitatum extract and medicinal composition preparation thereof |
| 03/24/2004 | CN1483457A Method for producing Huafenliuwei pill |
| 03/24/2004 | CN1483424A Lithagogue decoction |
| 03/24/2004 | CN1142996C Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same |
| 03/24/2004 | CN1142920C Quinazoline derivatives and pharmaceutical compositions containing them and preparation process and use |
| 03/24/2004 | CN1142918C Carboxylic acid derivs, their preparation and their use |
| 03/24/2004 | CN1142910C Amide compounds |
| 03/24/2004 | CN1142778C Use of thiazolium compounds for preventing and preventing the formation of advanced glycosylation endproducts |
| 03/23/2004 | US6710209 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
| 03/23/2004 | US6710067 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/23/2004 | US6710054 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 03/23/2004 | US6710052 Anticancer agents |
| 03/23/2004 | US6710043 Possess the potentiation of the cholinergic activity |
| 03/23/2004 | US6709831 DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof |
| 03/23/2004 | US6709651 Administering peptidase; substance p antagonist; central nervous system disorders |
| 03/23/2004 | CA2263319C Quinazoline derivatives and pharmaceutical compositions containing them |
| 03/23/2004 | CA2168432C Piperazine compounds used in therapy |
| 03/18/2004 | WO2004022716A2 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | WO2004022551A1 Furan or thiophene derivative and medicinal use thereof |
| 03/18/2004 | WO2004022538A1 Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same |
| 03/18/2004 | WO2004022529A2 Diarylurea derivatives and their use as chloride channel blockers |
| 03/18/2004 | WO2004022048A1 Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract |
| 03/18/2004 | WO2004022045A1 Hypogastric and/or perineal pain-relieving agent |
| 03/18/2004 | WO2004002983A3 Therapeutic piperazine derivatives useful for treating pain |
| 03/18/2004 | WO2003099192A3 Bis-aromatic alkanols |
| 03/18/2004 | WO2003097608A3 Opioid and opioid-like compounds and uses thereof |
| 03/18/2004 | WO2003094921A3 Utilization of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy |
| 03/18/2004 | WO2003087094A3 Pyrrolidinium derivatives as antagonists of m3 muscarinic receptors |
| 03/18/2004 | WO2003066595A3 2 - piperazine - pyridines useful for treating pain |
| 03/18/2004 | WO2003039434A3 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 03/18/2004 | WO2003033524A3 Peptidyl ketones as inhibitors of dpiv |
| 03/18/2004 | WO2003015704A3 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 03/18/2004 | WO2002055694A3 Discriminative nucleic acid analysis using clone sequence signatures |
| 03/18/2004 | US20040054187 Therapeutic ureas |
| 03/18/2004 | US20040054180 Kinase inhibitors; antiinflammatory agents; respiratory system disorders; cardiovascular disorders; antidiabetic agents |
| 03/18/2004 | US20040054145 Truncated cd200 |
| 03/18/2004 | US20040054001 For preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB, particularly psoriasis |
| 03/18/2004 | US20040053982 Such as 3-(2-(6-methyl-pyridin-2-ylamino)-5-(1,2,4)triazol-1-yl-thiazol-4 -yl)benzonitrile for treatment of inflammatory or obstrucive airways diseases |
| 03/18/2004 | US20040053977 Such as N-pyridin-2-yl-N'-(1-pyridin-2-yl-ethylidene)hydrazine for increasing erythropoietin levels and vascularization of tissue; antihypoxic agents |
| 03/18/2004 | US20040053957 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization |
| 03/18/2004 | US20040053955 An immunosuppressants for treating allograft rejection, transplant rejection, psoriasis, and rheumatoid arthritis, a 9,10-dihydro-9-oxo-acridine-3-yl- derivatives |
| 03/18/2004 | US20040053953 Treatment of chemokine mediated diseases |
| 03/18/2004 | US20040053951 Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use |
| 03/18/2004 | US20040053942 Fused pyrazole derivatives bieng protein kinase inhibitors |
| 03/18/2004 | US20040053931 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors |
| 03/18/2004 | US20040053924 Reacting pyrrolo(2,3-d)pyrimidin-4-one derivative containing a leaving group with a aromatic or heteroaromatic amine, hydroxy, marcaptan etc. in presence of a polar solvent and a catalyst |
| 03/18/2004 | US20040053921 Compounds useful as reversible inhibitors of cysteine proteases |
| 03/18/2004 | US20040053898 For organ specific therapy; for treatment of menopausal symptoms, hormone-deficiency diseases and neurodegenerative diseases |
| 03/18/2004 | US20040053897 Selective androgen receptor modulators (SARMs); for inhibition of mitogenic action of testosterone and dihydrotestosterone; also for treatment of hair loss |
| 03/18/2004 | US20040053842 Cholesterol ester transfer protein inhibitors for use in treating atherosclerosis optionally in combination with other antihypertensive agents |
| 03/18/2004 | US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 03/18/2004 | US20040053817 Proinsulin C-peptide is present in an absorbable matrix of polyglycolide-lactide copolymers; antidiabetic agents |
| 03/18/2004 | US20040053357 Nucleic acid encoding kv10.1 a voltage-gated potassium channel from human brain |
| 03/18/2004 | US20040053281 Comprises enzymatic polypeptide associated with fatty acid metabolism for diagnosing, treating and preventing cancer, neurodegenerative, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders |
| 03/18/2004 | US20040053278 Smad6 and uses thereof |
| 03/18/2004 | US20040052870 Cyclooxygenase (COX-2) inhibitors; for treatment/prevention of inflammation; nutraceuticals; for treatment of nervous system disorders |
| 03/18/2004 | US20040052786 Erbb4 antagonists |
| 03/18/2004 | CA2498297A1 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | CA2497901A1 Furan or thiophene derivative and medicinal use thereof |
| 03/18/2004 | CA2497464A1 A therapeutic agent for improving hypogastric and/or perineal pains |
| 03/18/2004 | CA2495284A1 Diarylurea derivatives and their use as chloride channel blockers |
| 03/17/2004 | EP1398036A1 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 03/17/2004 | EP1398030A2 Dipeptidyl peptidase IV effectors |
| 03/17/2004 | EP1398027A1 Use of matrix metalloproteinase inhibitors for treating or preventing glomerulopathy |
| 03/17/2004 | EP1397364A1 Novel pyrrole derivatives as pharmaceutical agents |
| 03/17/2004 | EP1397363A1 5-ethyl-imidazotriazinones |
| 03/17/2004 | EP1397361A1 Carboline derivatives as pdev inhibitors |
| 03/17/2004 | EP1397360A1 Azaindoles |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397356A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397355A1 Pyridyl cyanoguanidine compounds |
| 03/17/2004 | EP1397340A2 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 03/17/2004 | EP1397327A2 DEUTERATED N-SUBSTITUTED AND $g(a)-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
| 03/17/2004 | EP1397163A2 Method for the diagnosis and therapy of renal cell carcinoma |
| 03/17/2004 | EP1397159A2 Stable liquid formulations of antibodies |
| 03/17/2004 | EP1397153A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 03/17/2004 | EP1397131A1 Compositions comprising nitrofurantoin and uva ursi |
| 03/17/2004 | EP1397129A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors |
| 03/17/2004 | EP1397128A1 Kappa opiate agonists for the treatment of bladder diseases |
| 03/17/2004 | EP1397044A1 Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
| 03/17/2004 | EP1242406B1 Novel compounds |
| 03/17/2004 | EP1242364B1 Adamantane derivatives |